Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASH 2022
Updated MCL and CLL data from the ongoing Phase 1/2 study of zilovertamab and ibrutinib are encouraging and continue to improve over prior reporting The ORR of 89% and CR rate of 43% for patients with MCL treated with zilovertamab plus ibrutinib compare …